{"ORPHApacket":[{"ORPHApacketID":"235936","date":"2019-07-19 07:44:29","version":"1.2.11 \/ 4.1.6 [2018-04-12] (orientdb version)","copyright":"Orphanet (c) 2019","ORPHA":"235936","Name":[{"lang":"en","label":"Familial hyperaldosteronism"}],"PURL":"http:\/\/www.orpha.net\/ORDO\/Orphanet_235936","DisorderType":[{"Name":[{"lang":"en","label":"Group of phenomes"}],"PURL":"http:\/\/www.orpha.net\/ORDO\/Orphanet_377794"}],"SubClassOfList":[{"Disorder":[{"Name":[{"lang":"en","label":"Rare non surgically correctable form of primary aldosteronism"}],"ORPHA":"231641","PURL":"http:\/\/www.orpha.net\/ORDO\/Orphanet_231641"},{"Name":[{"lang":"en","label":"Genetic hyperaldosteronism"}],"ORPHA":"371861","PURL":"http:\/\/www.orpha.net\/ORDO\/Orphanet_371861"}]}],"TextSection":[{"Name":[{"lang":"en","label":"Disease definition"}],"Contents":"Familial hyperaldosteronism (FH) is the heritable form of primary aldosteronism (PA) which comprises three identified subtypes to date: FH type I (FH-I; see this term) characterized by early-onset hypertension, glucocorticoid remediable adrenocorticotropic hormone (ACTH)-dependent hyperaldosteronism, variable hypokalemia, and overproduction of 18-oxocortisol and 18-hydroxycortisol; FH type II (FH-II; see this term) characterized by hypertension of varying severity and hyperaldosteronism not suppressible by dexamethasone; and FH type III (FH-III; see this term) characterized by profound hypokalemia, early-onset severe hypertension, non glucocorticoid-remediable hyperaldosteronism, and overproduction of 18-oxocortisol and 18-hydroxycortisol."}],"AverageAgeOfOnsetList":[{"count":"1","AverageAgeOfOnset":[{"Name":[{"lang":"en","label":"All ages"}]}]}],"TypeOfInheritanceList":[{"count":"1","TypeOfInheritance":[{"Name":[{"lang":"en","label":"Autosomal dominant"}]}]}],"SynonymList":[{"count":"1","Synonym":[{"lang":"en","label":"FH"}]}]}]}